Laura Sun , Gaybrielle Moore , Annalise Labatut , Jane Meisel , Kevin Kalinsky , Kristina Byers
{"title":"Administration of trastuzumab deruxtecan in metastatic breast cancer patients with severe hepatic impairment","authors":"Laura Sun , Gaybrielle Moore , Annalise Labatut , Jane Meisel , Kevin Kalinsky , Kristina Byers","doi":"10.1016/j.cpccr.2024.100337","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Trastuzumab deruxtecan (T-DXd) shows efficacy in HER2-positive and HER2-low metastatic breast cancer (MBC), but its safety in patients with hepatic impairment is unclear.</div></div><div><h3>Methods</h3><div>We report three cases of MBC patients with significant liver dysfunction treated with dose-reduced T-DXd after multiple prior therapies.</div></div><div><h3>Results</h3><div>Dose-reduced T-DXd led to improved bilirubin levels and tumor response, with two patients achieving durable responses and enhanced quality of life. Supportive care and tailored dosing were crucial in managing hepatotoxicity.</div></div><div><h3>Conclusion</h3><div>Dose-reduced T-DXd may offer clinical benefit for MBC patients with liver impairment. Further studies are warranted to refine dosing strategies in this population.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"16 ","pages":"Article 100337"},"PeriodicalIF":0.2000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621924000590","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Trastuzumab deruxtecan (T-DXd) shows efficacy in HER2-positive and HER2-low metastatic breast cancer (MBC), but its safety in patients with hepatic impairment is unclear.
Methods
We report three cases of MBC patients with significant liver dysfunction treated with dose-reduced T-DXd after multiple prior therapies.
Results
Dose-reduced T-DXd led to improved bilirubin levels and tumor response, with two patients achieving durable responses and enhanced quality of life. Supportive care and tailored dosing were crucial in managing hepatotoxicity.
Conclusion
Dose-reduced T-DXd may offer clinical benefit for MBC patients with liver impairment. Further studies are warranted to refine dosing strategies in this population.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
